Hims & Hers Health, Inc.: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion.
1. Hims & Hers faces class action from investors over deceptive practices.
2. Company's collaboration with Novo Nordisk was terminated citing safety concerns.
3. Shares fell over 34% following announcement of partnership termination.
4. Lawsuit claims misleading statements impacted share price during Class Period.
5. Investors can file claims until August 25, 2025.
The loss of a significant partnership with Novo Nordisk suggests severe operational risks. Historical cases, such as Valeant Pharmaceuticals, show rapid stock declines following collaborations ending under similar circumstances.
How important is it?
The litigation against Hims & Hers could significantly deter investment interest. Legal issues in telehealth can raise regulatory scrutiny.
Why Short Term?
The immediate impact of share price drop indicates high volatility. Class actions can lead to lasting reputational damage but usually play out short-term.
Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Hims & Hers Health, Inc. ("Hims & Hers Health" or the "Company") (NYSE:HIMS) investors of a class action representing investors that bought securities between April 29, 2025 and June 23, 2025, inclusive (the "Class Period"). Hims & Hers Health investors have until August 25, 2025 to file a lead plaintiff motion.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.
CASE ALLEGATIONS: Hims & Hers is a telehealth company offering prescription and over-the-counter medications, as well as personal care products. According to the Complaint, on April 29, 2025, the company announced a long-term collaboration with Novo Nordisk A/S, beginning with the immediate sale of a bundled offering of Novo Nordisk's FDA-approved weight loss drug, Wegovy®, on the Hims & Hers platform.
The class action lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose material facts, including that: (i) Hims & Hers was engaged in the deceptive promotion and sale of illegitimate, knockoff versions of Wegovy®, thereby putting patient safety at risk; and (ii) as a result, there was a significant risk that Novo Nordisk would terminate its collaboration with the company.
The Complaint further alleges that on June 23, 2025, Novo Nordisk issued a press release announcing the termination of its partnership with Hims & Hers, citing "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk." Following this announcement, shares of Hims & Hers fell more than 34%, according to the Complaint.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq. Admitted CA and NY Bar lesley@portnoylaw.com 310-692-8883 www.portnoylaw.com
